Vertex Pharmaceuticals Inc (VRTX)
400.09
-2.09
(-0.52%)
USD |
NASDAQ |
May 02, 16:00
397.57
-2.52
(-0.63%)
After-Hours: 17:09
Vertex Pharmaceuticals Research and Development Expense (Annual): 3.163B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.163B |
| December 31, 2022 | 2.540B |
| December 31, 2021 | 1.938B |
| December 31, 2020 | 1.830B |
| December 31, 2019 | 1.754B |
| December 31, 2018 | 1.416B |
| December 31, 2017 | 1.325B |
| December 31, 2016 | 1.048B |
| December 31, 2015 | 995.92M |
| December 31, 2014 | 855.51M |
| December 31, 2013 | 882.10M |
| December 31, 2012 | 765.90M |
| December 31, 2011 | 707.71M |
| December 31, 2010 | 637.42M |
| December 31, 2009 | 550.27M |
| Date | Value |
|---|---|
| December 31, 2008 | 516.91M |
| December 31, 2007 | 513.05M |
| December 31, 2006 | 371.71M |
| December 31, 2005 | 248.54M |
| December 31, 2004 | 192.16M |
| December 31, 2003 | 199.64M |
| December 31, 2002 | 198.34M |
| December 31, 2001 | 141.99M |
| December 31, 2000 | 102.44M |
| December 31, 1999 | 72.20M |
| December 31, 1998 | 58.70M |
| December 31, 1997 | 51.60M |
| December 31, 1996 | 35.20M |
| December 31, 1995 | 41.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.754B
Minimum
2019
3.163B
Maximum
2023
2.245B
Average
1.938B
Median
2021
Research and Development Expense (Annual) Benchmarks
| Amgen Inc | 4.784B |
| Eli Lilly and Co | 9.313B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Alpine Immune Sciences Inc | 80.90M |
| Moderna Inc | 4.845B |